Ascentage Pharma Group International (AAPG) Accounts Payables (2023 - 2026)

Ascentage Pharma Group International's Accounts Payables history runs 3 years deep, the most recent figure standing at $15.0 million for Q4 2025.

• In Q4 2025, Accounts Payables rose 17.55% year-over-year to $15.0 million; the TTM figure through Dec 2025 stood at $15.0 million (up 17.55% YoY), while the FY2025 annual figure was $15.3 million, up 21.15% from the prior year.
• Accounts Payables for Q4 2025 stood at $15.0 million, down from $16.6 million in the prior quarter.
• The five-year high for Accounts Payables was $16.6 million in Q2 2025, with the low at $10.1 million in Q4 2023.
• The 3-year median for Accounts Payables is $13.9 million (2024), against an average of $13.6 million.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables gained 27.25% in 2024, then grew 17.55% in 2025.
• Ascentage Pharma Group International's Accounts Payables stood at $10.1 million in 2023, then increased by 27.25% to $12.8 million in 2024, then grew by 17.55% to $15.0 million in 2025.
• Business Quant data shows AAPG's Accounts Payables at $15.0 million in Q4 2025, $16.6 million in Q2 2025, and $12.8 million in Q4 2024.